Abstract
This correspondence critiques a 2025 study by Tsenov et al. on hypertrophic cardiomyopathy, highlighting discrepancies in reported symptom burden, psychological support, employment impact, diagnostic delays, activity restrictions, and medication tolerability. Recent evidence suggests improved outcomes with novel therapies and integrated care, challenging the study's conclusions. We advocate for reconciled analyses and future longitudinal studies to enhance patient-centered hypertrophic cardiomyopathy management.